ReviewCancer control : journal of the Moffitt Cancer Center2016
Developments in Intralesional Therapy for Metastatic Melanoma.
Review in Cancer control : journal of the Moffitt Cancer Center, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03233828 (Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2), which is not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?Frontiers in immunologyPooled it
- First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0.Molecular cancer therapeutics · 2024Trial
- Comparative real-world outcomes of stage III melanoma patients treated with talimogene laherparepvec or interleukin 2.Therapeutic advances in medical oncology · 2025Article
- Efficacy of Bacillus Calmette-Guérin in Cancer Prevention and Its Putative Mechanisms.Journal of cancer prevention · 2024Review
- Molecular distribution in intradermal injection for transfer and delivery of therapeutics.Frontiers in drug delivery · 2023Article
- Synergistic In Vitro Anticancer Toxicity of Pulsed Electric Fields and Glutathione.International journal of molecular sciences · 2022Article
- Detailed Structural Analysis of the Immunoregulatory Polysaccharides from the Mycobacterium Bovis BCG.Molecules (Basel, Switzerland) · 2022Article
- The role of HIF-1α in BCG-stimulated macrophages polarization and their tumoricidal effects in vitro.Medical microbiology and immunology · 2021Article
- BCG turns 100: its nontraditional uses against viruses, cancer, and immunologic diseases.The Journal of clinical investigation · 2021Review
- Current status of intralesional agents in treatment of malignant melanoma.Annals of translational medicine · 2021Review
- Case Report: Combined Intra-Lesional IL-2 and Topical Imiquimod Safely and Effectively Clears Multi-Focal, High Grade Cutaneous Squamous Cell Cancer in a Combined Liver and Kidney Transplant Patient.Frontiers in immunology · 2021Review
- Application of COMelanoma management · 2019Article
- Spotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodes.Oncolytic virotherapy · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundLocoregional advanced melanoma poses a complex clinical challenge that requires a multidisciplinary, patient-centered approach. Numerous agents have been studied for their suitability as intralesional therapy in the past decades, but few have successfully completed phase 3 clinical trial testing.
methodsThe relevant medical literature was searched for articles regarding use of intralesional therapies in metastatic melanoma. Therapies with data from phase 2 or higher studies were selected for review. This review also summarizes the mechanisms of action, adverse-event profiles, and clinical data for these agents.
resultsIntralesional therapies demonstrate promising effects in select patients with advanced melanoma. The optimal approach should be individually tailored and consist of a combination of intralesional therapies, regional perfusions, systemic immunotherapies, targeted therapies, and surgery, if necessary.
conclusionsDue to its relatively good local response rates and tolerable adverse-event profile, intralesional therapy may be a treatment option for select patients with unresectable, locally advanced or metastatic melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.